No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 40 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 11.2x · 10Y median 38.4x · 19th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:50:19.777Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:50:19.777Z. Latest historical point 2026-08-13.
The latest delayed quote for Abeona Therapeutics Inc. (ABEO) stock was $5.01 as of Oct 6, 2026, 1:50 PM EDT, down 2.05% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -5.5% · 3-year avg +5.9%/yr · 5-year avg -26.5%/yr
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases.
Biotechnology · Cleveland, OH
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.14
Revenue Est.
$16.48M
Last Quarter Results
EPS
$-0.35
vs Estimate
$-0.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ABEO | $285.26M | $5.00 | -2.05% | -5.53% | -26.46% | -29.45% | N/A |
| 2SGMT | $286.39M | $8.79 | -2.66% | +23.74% | N/A | N/A | vs ABEO |
| 3LAB | $287.26M | $0.73 | -3.83% | -42.91% | -32.98% | -20.93% | vs ABEO |
| 4INDP | $283.11M | $2.50 | -0.40% | -23.14% | -58.32% | -57.48% | vs ABEO |
| 5FULC | $281.16M | $3.69 | -0.67% | -59.59% | -31.70% | N/A | vs ABEO |
| 6ACB | $280.29M | $4.53 | +1.46% | -20.97% | -42.83% | -30.23% | vs ABEO |
forward FY estimate
N/A
$11.38M
vs Estimate
$12.24M
Consensus Rating
Based on 8 analysts
Average Price Target
$18.88
+277.1% upside
Low
$14.00
Current
$5.00
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.25 | $-0.14 | $0.03 | 4 |
| Quarter ending Dec 2026 | $-0.27 | $-0.10 | $0.10 | 4 |
| Quarter ending Mar 2027 | $-0.10 | $-0.07 | $-0.04 | 1 |
| Quarter ending Jun 2027 | $-0.03 | $-0.02 | $-0.01 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.19 | $-0.91 | $-0.52 | 6 |
| FY 2027 | $-0.47 | $-0.09 | $0.47 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $10.39M | $16.48M | $24.76M | 6 |
| Quarter ending Dec 2026 | $13.55M | $19.20M | $26.69M | 6 |
| Quarter ending Mar 2027 | $15.08M | $23.27M | $32.17M | 3 |
| Quarter ending Jun 2027 | $17.74M | $27.36M | $37.83M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $45.92M | $55.80M | $72.23M | 7 |
| FY 2027 | $88.78M | $121.22M | $172.08M | 7 |
